STOCK TITAN
  1. Home
  2. News
  3. CLVT

Clarivate Plc - CLVT STOCK NEWS

Welcome to our dedicated news page for Clarivate Plc (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Clarivate Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Clarivate Plc's position in the market.

News
Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report
Rhea-AI Summary
Clarivate Plc (CLVT) Releases Annual Drugs to Watch Report, Predicts 13 New Therapeutics to Achieve Blockbuster Status by 2029
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6%
Tags
none
-
News
Clarivate Reveals Stronger Outlook for Pulsed-field Ablation Market and Potential for Device to Revolutionize Treatment Paradigm
Rhea-AI Summary
Clarivate Plc (NYSE:CLVT) Launches Electrophysiology Mapping and Ablation Devices Market Insights Report Series, Predicts Pulsed-Field Ablation to Revolutionize EP Mapping and Ablation Device Market
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.31%
Tags
none
-
News
Clarivate Expands Partnership with VeriSIM Life to Accelerate and De-risk Research and Drug Development
Rhea-AI Summary
Clarivate Plc (CLVT) launches VeriSIM Life Translational Index™ on Cortellis Drug Discovery Intelligence, providing pharma and biotech companies with predictive compound safety and efficacy insights. The integrated workflow aims to minimize late-stage failures during clinical trials, leveraging AI to reduce research and development time and increase clinically active compound candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.87%
Tags
partnership
News
Clarivate Reveals World';s Influential Researchers in Highly Cited Researchers 2023 List
Rhea-AI Summary
Clarivate Plc (NYSE:CLVT) reveals its 2023 list of Highly Cited Researchers™, recognizing influential researchers globally. The evaluation process draws on data from the Web of Science™ citation index, with 6,849 researchers from over 1,300 institutions in 67 nations and regions. Key findings show a concentration of top talent, with 10 countries representing over 80% of the list. The US leads with 37.5%, followed by Mainland China with 17.9%. The Chinese Academy of Sciences tops the list with 270 recognitions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
none
-
News
Clarivate to Present at the RBC Capital Markets 2023 Technology, Internet, Media and Telecommunications Conference on November 14, 2023
Rhea-AI Summary
Clarivate Plc (NYSE: CLVT) announced that CEO Jonathan Gear will present at the RBC Capital Markets 2023 Technology, Internet, Media and Telecommunications Conference on November 14, 2023 at 1:20 pm Eastern Time. The live webcast can be accessed at https://www.veracast.com/webcasts/rbc/tmit2023/67C540.cfm and will be available for replay.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.67%
Tags
conferences
-
News
Clarivate Reports Third Quarter 2023 Results
Rhea-AI Summary
Clarivate Plc reported third-quarter revenues of $647.2 million, a 1.8% increase, and a net loss of $6.6 million. The company reaffirmed its 2023 outlook, showing improved performance driven by organic growth in its segments. Revenues for the nine months ended September 30, 2023, were $1,945.1 million, a 2.0% decrease, and a net loss of $123.6 million. The company's adjusted EBITDA increased by 3.6% to $281.4 million for the third quarter, and by 1.3% to $819.0 million for the nine months ended September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
earnings
News
Clarivate Report Reveals China Challenging U.S. Research Dominance, Signaling Future Research Ambitions
Rhea-AI Summary
China's research economy has seen a dramatic increase in quality and its research is increasingly valued beyond its borders, according to a report from the Institute for Scientific Information (ISI). China's research output has increased five-fold between 2009 and 2021, surpassing the U.S. and E.U. in published research. China's proportion of published research with citation impact above the global average now matches the U.S. and Germany. Additionally, China has over 1,000 Highly Cited Papers per year, indicating global recognition and collaboration with Chinese researchers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Clarivate Partners with EveryLibrary to Support and Nurture Libraries in the U.S.
Rhea-AI Summary
Clarivate Plc has announced a partnership with EveryLibrary to support libraries in the US. The partnership aims to advance EveryLibrary's mission to safeguard and support libraries by providing dedicated resources and advocacy. Clarivate is committed to promoting literacy, education, and equal access to information through this partnership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
-
News
BioWorld by Clarivate Examines Impact of Emerging Medicines on Obesity
Rhea-AI Summary
BioWorld™ published by Clarivate Plc examines the impact of emerging obesity medicines in a new three-part series. Over $1 billion of investment is anticipated in obesity through licensing or M&As in 2023, with the overall market expected to climb upwards of $50 billion in the coming years. Novo Nordisk recently reported sales of Wegovy totaling $1.7 billion for the first half of 2023, up 367% over the prior year. Sales of Ozempic, a lower-dose version of semaglutide, are up 58% year over year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
acquisition
News
Clarivate Renews Partnership with The Federal Library and Information Network
Rhea-AI Summary
Clarivate renews contract with FEDLINK to provide comprehensive solutions to government libraries
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.15%
Tags
partnership
Stock CLVT logo
Clarivate Plc

NYSE:CLVT

CLVT Rankings

#1229 Ranked by Market Cap
#4260 Ranked by Stock Gains
N/A Ranked by Dividends

CLVT Stock Data

4.72B
404.04M
16.65%
92.2%
5.52%
Data Processing, Hosting, and Related Services
Information
Link
United Kingdom
160 Blackfriars Road

About CLVT

clarivate analytics is the global leader in providing trusted insights and analytics to accelerate the pace of innovation. we offer some of the most trusted brands across the innovation lifecycle, including web of science™, cortellis™, derwent™, compumark™, markmonitor® and techstreet™. organizations and researchers rely on the curated knowledge bases from clarivate for information about scientific and academic research, patent analytics, pharmaceutical and biotech intelligence and ip management. an independent company with over 4,000 employees and operations in more than 100 countries, clarivate is on a bold entrepreneurial mission to help radically reduce the time from new ideas to life-changing innovations. for more information, please visit clarivate.com.